Supplier News: Kindeva, Gattefossé, Ritedose & More
The latest from CDMOs, CMOs, and suppliers featuring Kindeva and Gattefossé.
Formulation Development/Drug Product Manufacturing
* Kindeva Opens New UK HQ and Propellant Mfg Facility
* Gattefossé Opens New Excipient Mfg Facility
* Ritedose Expands Analytical Capabilities
Appointments
* Pharm Tech Industries Names Sr. Managing Advisor, Commercial Ops
Formulation Development/Drug Product Manufacturing
Kindeva Opens New UK HQ and Propellant Mfg Facility
Kindeva has officially opened its new UK headquarters at Charnwood Campus Science Innovation and Technology Park, Loughborough, UK. The facility represents an expansion in Kindeva’s metered-dose inhaler services, and the facility will develop and test next-generation propellants (NGP) as the industry prepares to move to more environmentally friendly products.
The 150,000-square-foot site offers a range of services across drug development from early-stage viability, analytical method development, to commercial analysis. The Loughborough HQ will be responsible for developing and analyzing NGPs as the industry faces legislation aimed at reducing the environmental impact of the propellants currently used in pressurized metered-dose inhalers (pMDIs).
Source: Kindeva
Gattefossé Opens New Excipient Mfg Facility
Gattefossé, a provider of specialty ingredients and formulation solutions for pharmaceutical and personal care products, has opened a new manufacturing facility in Lufkin, Texas. The Lufkin plant is dedicated to lipid-based excipients and was designed with the dual objective of increasing production capacity and reinforcing Gattefossé’s presence in North America.
Source: Gattefossé
Ritedose Expands Analytical Capabilities
The Ritedose Corporation, a CDMO focused on blow-fill-seal technology, is investing more than $17 million to further its in-house cGMP laboratory capabilities by expanding its analytical chemistry and microbiology laboratories in Columbia, South Carolina.
The two new lab spaces will triple Ritedose’s current lab footprint to 10,000 square feet and will be expanded in two phases, with construction of both phases scheduled for completion in the spring of 2026. Phase I consists of a 10,000-square-foot analytical chemistry laboratory, housed in the company’s newly opened distribution and logistics facility located at Ritedose Performance Park. The new facility will create a clear separation between wet-lab operations and office areas; the company’s existing analytical laboratory combines office and lab functions in a single space. Phase II of the expansion converts the company’s current analytical chemistry lab space (located in Ritedose’s main building) into a 6,000-square foot expansion of microbiology lab services.
Source: Ritedose
Appointments
Pharm Tech Industries Names Sr. Managing Advisor, Commercial Ops
Pharma Tech Industries, a provider of contract manufacturing and packaging solutions, has appointed Sam Ricchezza, currently Senior Business Advisor/Chief Alliance Officer for SPEC Labs Center for Advancement of Biomedical Innovation, as its new Senior Managing Advisor, Commercial Operations.
Most recently, he served as Senior Business Advisor/Chief Alliance Officer for the Canada-based not-for-profit SPEC Labs Center for Advancement of Biomedical Innovation. Prior to that, he was Head of CDMO Business Unit Strategy and Market Insights for Emergent BioSolutions, where he was instrumental in identifying, directing and supporting business case design, technology scouting, and operational improvements for long-term value creation.
Earlier in his career, Ricchezza held a string of upwardly mobile roles, including President of North America Operations at Bora Pharmaceuticals, President of WellSpring Pharma Services, and Senior Business Advisor, Marketing and Sales Strategy for the Center for Commercialization of Regenerative Medicine.
Source: Pharma tech Industries
